COVAXIN information

Indian Council for Medical Research (ICMR, New Delhi)

Information on the vaccine (Bharat Biotech)


Pre-clinical (1) Immunogenecity and protective efficiency in hamsters iScience proof (pdf) (2) Immunogenecity and protective efficiency in rhesus macaques (preprint pdf)m (3) Safety immunogenecity (preprint bioRxiv 2020 Sep; published 2021 Jan Lancet)


Phase I  Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine BBV152 (preprint medRxiv; published 2021 March Lancet)

Salient features (Bharat Biotech)

Phase II Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report (preprint medRxiv: 20 December 2020. Published in The Lancet: Infectious Diseases 2021 March.)

Salient features (Bharat Biotech)

Phase III Bharat Biotech Announces Phase 3 Results of COVAXIN®: India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

Vaccine drive Restricted use in emergency situation (Letter 3 Jan 2021)


updated 7 May, 2021

This entry was posted in Science, Science literacy, Society. Bookmark the permalink.

Leave a Reply

Your e-mail address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.